Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
22 Feb 2016 01:39 PM
RNS
Result of GM
15 Feb 2016 07:00 AM
RNS
US PATIENTS COMMENCE DOSING IN PHASE III STUDY
05 Feb 2016 12:22 PM
RNS
Placing and Subscription Raises £8.3 million
05 Feb 2016 07:00 AM
RNS
Proposed Placing and Subscription
21 Jan 2016 05:33 PM
RNS
Holding(s) in Company
15 Dec 2015 07:00 AM
RNS
ImmuPharma & Simbec-Orion - Investigators Meeting
07 Dec 2015 07:00 AM
RNS
Update on the progress of Lupuzor
30 Nov 2015 11:55 AM
RNS
Holding(s) in Company
04 Nov 2015 08:26 AM
RNS
Lupuzor Phase III Pivotal Trial Update
04 Nov 2015 07:00 AM
RNS
Lupuzor Phase III Pivotal Trial Update
23 Oct 2015 07:00 AM
RNS
Directorate Change
30 Sep 2015 07:05 AM
RNS
Directorate Change
30 Sep 2015 07:00 AM
RNS
Interim Results
29 Jul 2015 07:00 AM
RNS
Richard Warr
27 Jul 2015 07:00 AM
RNS
TERM SHEET SIGNED $14 MILLION FUNDING FOR LUPUZOR
25 Jun 2015 07:00 AM
RNS
Lupuzor's Founder Dr Slyviane Muller Awarded Medal
29 May 2015 12:50 PM
RNS
Result of AGM
06 May 2015 03:44 PM
RNS
Annual Report & Accounts
06 May 2015 07:02 AM
RNS
Interim Board Change
30 Apr 2015 07:05 AM
RNS
Directorate Change
30 Apr 2015 07:00 AM
RNS
Preliminary Results
11 Feb 2015 12:02 PM
RNS
CANCER UPDATE: IPP-204106
27 Jan 2015 07:00 AM
RNS
Enterprise Investment Scheme Status
22 Jan 2015 07:00 AM
RNS
Collaboration Agreement with Simbec-Orion
30 Oct 2014 11:10 AM
RNS
Holding(s) in Company
28 Oct 2014 07:00 AM
RNS
Holding(s) in Company
21 Oct 2014 07:00 AM
RNS
Additional Listing - Conditional Placing
20 Oct 2014 07:00 AM
RNS
ImmuPharma awarded EUR400,000 Grant
30 Sep 2014 07:05 AM
RNS
Half Yearly Report
30 Sep 2014 07:00 AM
RNS
LupuzorT Gears Up To Start Pivotal Phase III trial
27 Jun 2014 01:11 PM
RNS
Result of AGM
27 Jun 2014 07:00 AM
RNS
Access to pioneering research in Bordeaux France
16 Jun 2014 07:00 AM
RNS
NEW NUCANT PATENTS
23 May 2014 07:00 AM
RNS
Annual Financial Report
21 May 2014 07:00 AM
RNS
Preliminary Results
06 May 2014 12:47 PM
RNS
Dr. Sylviane Muller - Presentation Abstract
23 Apr 2014 07:00 AM
RNS
Dr. S Muller, founder of Lupuzor presentation.
11 Apr 2014 07:00 AM
RNS
ImmuPharma Sponsors the 2014 European Lupus Confer
14 Oct 2013 07:00 AM
RNS
Additional Listing
27 Sep 2013 07:00 AM
RNS
Half Yearly Report
13 Aug 2013 07:00 AM
RNS
UPDATE CANCER PROGRAMME IPP-204106
31 Jul 2013 07:00 AM
RNS
FDA GRANTS IMMUPHARMA AMENDED SPA
08 Jul 2013 08:00 AM
RNS
IMMUPHARMA APPOINTS WORLDWIDE KEY OPINION LEADERS
05 Jun 2013 07:00 AM
RNS
Holding(s) in Company
23 May 2013 12:29 PM
RNS
Result of AGM
21 May 2013 07:00 AM
RNS
?50M Financing Facility - Darwin Strategic
22 Apr 2013 07:00 AM
RNS
Posting of Annual Report and AGM Notice
09 Apr 2013 07:00 AM
RNS
Preliminary Results
28 Feb 2013 07:01 AM
RNS
ImmuPharma Commences Trading on Stuttgart Exchange
28 Jan 2013 04:03 PM
RNS
Director/PDMR Shareholding - Replacement

ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France. 

ImmuPharma listed on AIM under the ticker IMM. 

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

IMM share price listed in London at 1,190p in 2000. 

UK 100

Latest directors dealings